CN116158532A - Application of lactobacillus plantarum grx16 in preparation of food, functional food and medicine with insulin resistance relieving function - Google Patents
Application of lactobacillus plantarum grx16 in preparation of food, functional food and medicine with insulin resistance relieving function Download PDFInfo
- Publication number
- CN116158532A CN116158532A CN202310279050.7A CN202310279050A CN116158532A CN 116158532 A CN116158532 A CN 116158532A CN 202310279050 A CN202310279050 A CN 202310279050A CN 116158532 A CN116158532 A CN 116158532A
- Authority
- CN
- China
- Prior art keywords
- insulin resistance
- grx16
- lactobacillus plantarum
- insulin
- amylase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 41
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 39
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 36
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 36
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 title claims abstract description 9
- 235000013376 functional food Nutrition 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000004382 Amylase Substances 0.000 claims abstract description 20
- 102000013142 Amylases Human genes 0.000 claims abstract description 20
- 108010065511 Amylases Proteins 0.000 claims abstract description 20
- 235000019418 amylase Nutrition 0.000 claims abstract description 20
- 229940125396 insulin Drugs 0.000 claims abstract description 15
- 102000004877 Insulin Human genes 0.000 claims abstract description 14
- 108090001061 Insulin Proteins 0.000 claims abstract description 14
- 102000011690 Adiponectin Human genes 0.000 claims abstract description 12
- 108010076365 Adiponectin Proteins 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 11
- 235000009200 high fat diet Nutrition 0.000 claims abstract description 11
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 9
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims abstract description 9
- 102100040918 Pro-glucagon Human genes 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 229940088597 hormone Drugs 0.000 claims abstract description 7
- 239000005556 hormone Substances 0.000 claims abstract description 7
- 230000000968 intestinal effect Effects 0.000 claims abstract description 5
- 230000028327 secretion Effects 0.000 claims abstract description 5
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 3
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 230000001965 increasing effect Effects 0.000 claims description 6
- 230000028709 inflammatory response Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000019626 lipase activity Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 102000004882 Lipase Human genes 0.000 abstract description 11
- 108090001060 Lipase Proteins 0.000 abstract description 11
- 239000004367 Lipase Substances 0.000 abstract description 11
- 235000019421 lipase Nutrition 0.000 abstract description 11
- 210000000496 pancreas Anatomy 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 25
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 102000038379 digestive enzymes Human genes 0.000 description 5
- 108091007734 digestive enzymes Proteins 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000015140 cultured milk Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- -1 sucrose ester Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to application of lactobacillus plantarum grx16 in preparation of foods, functional foods and medicines with an insulin resistance relieving function, wherein the preservation number of lactobacillus fermentum grx08 is CGMCC No:10921. the lactobacillus plantarum grx16 can relieve the rise of blood sugar and insulin caused by high-carbon and high-fat diet and reduce the insulin resistance index. Animal experiments prove that the lactobacillus plantarum grx16 (CGMCC No. 10921) can increase and regulate the level of insulin resistance related hormone glucagon-like peptide-1 and adiponectin, inhibit the activities of intestinal amylase and lipase and reduce pancreas secretion amylase, simultaneously regulate inflammatory reaction caused by high-fat diet, relieve the rise of blood sugar and insulin caused by high-carbon water and high-fat diet, reduce the insulin resistance index and further relieve insulin resistance.
Description
Technical Field
The invention relates to application of lactobacillus plantarum grx16 in preparation of foods, functional foods and medicines with an insulin resistance relieving function, and belongs to the technical field of biology.
Background
The modern diet structure change and high fat and high carbohydrate diets cause the metabolism of fat, carbohydrate and the like in the human body to be disturbed, so that obesity is caused. Insulin Resistance (IR) is the basis for the link between obesity and most of its associated metabolic disorders, including type 2 diabetes, fatty liver disease, dyslipidemia and cardiovascular disease, and is often manifested in the clinical manifestations of obesity. Insulin resistance is a chronic, non-specific, inflammatory process of inflammation, and inflammatory factors such as IL-6 affect post-insulin receptor signaling. Probiotics are capable of alleviating insulin resistance through a variety of pathways. In the existing clinical and animal experimental researches, probiotics can relieve insulin resistance by reducing blood sugar, insulin, blood fat, inflammatory factors and the like. In addition, probiotics inhibit the activity of digestive enzymes such as amylase and lipase in the intestinal tract, and reduce the digestive absorption of amylase and fat. The invention researches the insulin resistance relieving function of lactobacillus plantarum grx16 obtained by screening, and lays a foundation for developing foods, functional foods and medicines with the insulin resistance relieving function.
Disclosure of Invention
The invention aims at solving the problems existing in the prior art and provides application of lactobacillus plantarum grx16 in preparing foods, functional foods and medicines with an insulin resistance relieving function.
The aim of the invention is realized by the following technical scheme, the application of lactobacillus plantarum (Lactobacillus plantarum) grx16 in preparing foods, functional foods and medicines with the function of relieving insulin resistance is realized, and the preservation number of lactobacillus fermentum grx08 is CGMCC No:10921.
the lactobacillus plantarum grx16 can relieve the rise of blood sugar and insulin caused by high-carbon and high-fat diet and reduce the insulin resistance index.
The lactobacillus plantarum grx16 is capable of alleviating insulin resistance by increasing the level of glucagon-like peptide-1 and adiponectin, which are hormones involved in insulin resistance, inhibiting intestinal amylase and lipase activity, simultaneously inhibiting pancreatic secretion of amylase, and regulating inflammatory response caused by high-fat diet.
The invention has scientific and reasonable scheme, and discloses application of lactobacillus plantarum grx16 (CGMCC No. 10921) in foods, functional foods and medicines for relieving insulin resistance.
Animal experiments prove that the lactobacillus plantarum grx16 (CGMCC No. 10921) can increase and regulate the level of insulin resistance related hormone glucagon-like peptide-1 and adiponectin, inhibit the activities of intestinal amylase and lipase and reduce pancreas secretion amylase, simultaneously regulate inflammatory reaction caused by high-fat diet, relieve the rise of blood sugar and insulin caused by high-carbon water and high-fat diet, reduce the insulin resistance index and further relieve insulin resistance.
Drawings
FIG. 1 is a graph of insulin resistance determinations;
* Indicating that the different groups were significantly different (P < 0.05).
FIG. 2 is a graph of an insulin resistance-related hormone assay;
* Indicating that the different groups were significantly different (P < 0.05).
FIG. 3 is a graph of a rat intestinal digestive enzyme assay;
* Indicating that the different groups were significantly different (P < 0.05).
FIG. 4 is a graph of a rat pancreatic digestive enzyme assay;
* Indicating that the different groups were significantly different (P < 0.05).
FIG. 5 is a graph of inflammatory factor determination in rats;
* Indicating that the different groups were significantly different (P < 0.05).
Detailed Description
The research of Chinese patent ZL201510551144.0 has found that lactobacillus plantarum grx16 (CGMCC No. 10921) has the functions of in vitro antioxidation and alpha-glucosidase inhibition, and the invention further discovers that lactobacillus plantarum grx16 can relieve insulin resistance caused by high-carbon water and high-fat diet. The method comprises the steps of establishing a high-carbohydrate and high-fat diet rat model by feeding high-carbohydrate and high-fat feed, measuring the activity of Amylase (AMS) and Lipase (LPS) in pancreas and chyme of the rat after the lactobacillus plantarum grx16 is filled, and measuring the content of blood sugar (GLU), insulin (INS), glucagon-like peptide-1 (GLP-1), adiponectin (ADPN), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and nuclear factor kappa B (NF-kappa B) in serum of the rat, so as to evaluate the effect of the lactobacillus plantarum grx16 on relieving insulin resistance.
The method comprises the following specific steps
1 preparation of gastric lavage sample
The preserved lactobacillus plantarum grx16 is respectively activated, inoculated into MRS liquid culture medium according to the inoculation amount of 3 percent, cultured for 18 hours at 37 ℃, centrifuged for 10 minutes at 4000 Xg, and then the thalli are collected.
Lactobacillus plantarum grx16 bacterial suspension: the bacterial cells were collected by suspending in physiological saline and counted as colonies, and diluted to 1X 10 with physiological saline before feeding 9 CFU/mL。
2 grouping and modeling of animals
SPF-class SD male rats were kept 15 animals in a ventilated, light-transmitting and sanitary animal house at a room temperature of 23.0.+ -. 1.0 ℃ and a humidity of 50.+ -. 5%, and were fed with a high-carbon water base feed (flour 20%, rice flour 10%, corn 20%, drum skin 26%, bean material 20%, fish meal 2%, bone meal 2%), adapted to regular 12-hour day/12-hour night cycles, and then regrouped according to the average weight of each group without significant differences, and the remaining groups were fed with a normal feed by feeding 4 weeks of a high-carbon water high-fat feed (10% lard, 10% yolk powder, 1% cholesterol and 0.2% bile salt and 78.8% base feed) except for the blank group, to establish a high-fat rat model. After successful molding, the gastric lavage experiment was performed for 4 weeks, and the grouping and gastric lavage modes of rats are shown in table 1.
TABLE 1 grouping and treatment of high fat model animals
3 Effect of Mixed probiotics on insulin resistance
Insulin resistance refers to the decrease in the efficiency of insulin to promote glucose uptake and utilization for various reasons, and the compensatory hypersecretion of insulin by the body produces hyperinsulinemia to maintain the stability of blood glucose. Insulin resistance index is commonly used to reflect the degree of insulin resistance. Rat serum was taken, GLU concentration was determined using biochemical analysis, INS content was determined by ELISA kit, and insulin resistance index (HOMA-IR), HOMA-ir=fasting insulin x fasting blood glucose ≡22.5 was calculated. As can be seen from FIG. 1, the GLU and INS levels in the model rats were significantly increased (P < 0.05) compared to the blank rats. Lactobacillus plantarum grx16 intervention significantly reduced the INS content and HOMA-IR index (P < 0.05) from 51.07mU/L and 18.86 to 40.14mU/L and 12.02, respectively, compared to the model group, and was not significantly different from the blank group (P > 0.05). GLU was lowered compared to model, between model and blank, and was not significantly different from both model and blank (P > 0.05).
4 effects of mixed probiotics on the modulation of insulin resistance related hormones
Glucagon-like peptide-1 (GLP-1) is secreted by intestinal tracts and can stimulate insulin secretion, and can inhibit appetite through central nerves, so that the effect of reducing blood sugar is achieved, and the reduction of GLP-1 level can cause the damage of an 'incretin effect', so that the glucagon-like peptide-1 is an important target point for treating type 2 diabetes. Adiponectin (ADPN) is an insulin-sensitizing hormone secreted by adipose tissue, and can improve insulin resistance and has a certain anti-inflammatory effect. Rat serum was taken and the content of GLP-1 and ADPN in the rat serum was determined using ELISA kit. As can be seen from FIG. 2, the GLP-1 and ADPN content of the rats in the model group was significantly reduced (P < 0.05) compared with that in the blank group. Lactobacillus plantarum grx16 significantly increased GLP-1 and ADPN levels (P < 0.05) compared to the model group from 8.22pmol/L and 7.96 μg/mL to 10.04pmol/L and 14.05 μg/mL, respectively, with ADPN levels returning to the blank group levels, with a significant difference (P > 0.05) from the blank group.
5 Effect of Mixed probiotics on rat digestive enzyme Activity
The activities of digestive enzymes such as Amylase (AMS) and Lipase (LPS) in the intestinal tract affect the absorption of nutrients by rats, and the pancreas is the main organ for secretion of digestive enzymes. The pancreas and chyme homogenates were prepared from rat pancreas and duodenum, and the activity of AMS and LPS in the rat gut and pancreas was measured using amylase activity assay kit and lipase activity assay kit, respectively. As can be seen from FIG. 3, the activity of AMS and LPS in the intestinal tract of rats was significantly increased (P < 0.05) in the model group compared to the blank group. The dry prognosis of lactobacillus plantarum grx16 significantly reduced both AMS and LPS activity in the rat intestinal tract (P < 0.05) compared to the model group, from 0.61U/mg and 8.02U/mg to 0.38U/mg and 4.66U/mg, respectively, and no significant difference from the blank group (P > 0.05). As can be seen from FIG. 4, there was no significant difference in the levels of AMS and LPS in the pancreas of the model group (P > 0.05) compared to the blank group. After a dry prognosis of lactobacillus plantarum grx16, rat pancreatic AMS activity was significantly reduced (P < 0.05), from 7.75U/mg to 0.63U/mg.
6 influence of Mixed probiotics on rat inflammatory factor
Cytokines are important components of the body's defense system, both as products of and enhancing the immune response. TNF-alpha and IL-6 have wide biological activities and are considered to be important indicators reflecting the severity of inflammatory responses, and NF- κB, a multifunctional cellular transcription factor, plays an important role in pathological physiology such as inflammatory responses, apoptosis and the like. The content of inflammatory factors TNF-alpha, IL-6 and NF-kappa B in the rat serum is measured by ELISA kit. As can be seen from FIG. 5, the levels of TNF-alpha, IL-6 and NF-kappa B in the serum of rats in the model group were significantly increased (P < 0.05) as compared to the serum of rats in the blank group. The interference of lactobacillus plantarum grx16 significantly reduced the content of IL-6 and NF- κb in rat serum (P < 0.05) compared to the model group, from 146.96pg/mL and 1302.25pg/mL to 111.12pg/mL and 1032.01pg/mL, respectively, and all were not significantly different from the blank group (P > 0.05).
Application examples
Preparation of 1 Lactobacillus plantarum grx16 probiotic solid beverage
The lactobacillus plantarum grx16 and one or more of xylo-oligosaccharide, fructo-oligosaccharide, mulberry leaf extract, xylitol, natural fruit powder and the like are used as raw materials, and the specific proportion (mass percent) is as follows: lactobacillus plantarum grx16 powder (viable count 10) 11 CFU/g) 5-10%, xylo-oligosaccharide 15-25%, fructo-oligosaccharide 10-15%, mulberry leaf extract 3-5%, natural fruit powder 15-20% and xylitol 20-25%. Wherein the folium Mori extract is folium Mori water body (10:1). Mixing the raw materials, pulverizing, sieving, mixing, and packaging.
Preparation of 2 Lactobacillus plantarum grx16 fermented milk
Heating whole milk to about 50deg.C, adding 6% sucrose, dissolving, preheating to about 60deg.C, homogenizing under 20-25MPa, heat treating at 95deg.C for 5min, cooling to about 40deg.C, inoculating lactobacillus plantarum grx16 starter at an inoculum size of 3%, fermenting at 37deg.C to pH 4.2-4.5, cooling, and storing at 4deg.C.
Preparation of 3 Lactobacillus plantarum grx16 fermented milk beverage
350kg of reconstituted skim milk (containing 12% of skim milk powder), after full dissolution, heat treatment for 5min at 95 ℃, cooling to 37-40 ℃, inoculating lactobacillus plantarum grx16 starter according to 3.5% inoculum size, fermenting at 37 ℃ for about 24-26h, controlling the final acidity to be about 160-170 ℃, adding 650kg of mixed solution of sugar and stabilizer (the composition of the mixed solution is 12-14% sucrose, 0.1-0.15% monoglyceride, 0.1-0.15% sucrose ester and 0.4-0.8% pectin) after heat treatment for 5s at 110 ℃, and adding the mixed solution of the following components of the mixed solution
Homogenizing under 20-25MPa, cooling to 15-20deg.C, and aseptic packaging to obtain 1000kg lactobacillus plantarum
The grx16 fermented milk beverage was stored at 4 ℃.
Claims (3)
1. The application of lactobacillus plantarum grx16 in preparing foods, functional foods and medicines with the function of relieving insulin resistance, wherein the preservation number of lactobacillus fermentum grx08 is CGMCC No:10921.
2. the use according to claim 1, wherein lactobacillus plantarum grx16 is capable of alleviating the increase in blood glucose and insulin caused by high-carbon, high-fat diets, reducing the insulin resistance index.
3. The use according to claim 1, wherein lactobacillus plantarum grx16 is capable of alleviating insulin resistance by increasing the level of the insulin resistance associated hormones glucagon-like peptide-1 and adiponectin, inhibiting intestinal amylase and lipase activity, simultaneously inhibiting pancreatic secretion of amylase, and modulating the inflammatory response caused by a high fat diet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310279050.7A CN116158532A (en) | 2023-03-21 | 2023-03-21 | Application of lactobacillus plantarum grx16 in preparation of food, functional food and medicine with insulin resistance relieving function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310279050.7A CN116158532A (en) | 2023-03-21 | 2023-03-21 | Application of lactobacillus plantarum grx16 in preparation of food, functional food and medicine with insulin resistance relieving function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116158532A true CN116158532A (en) | 2023-05-26 |
Family
ID=86416497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310279050.7A Pending CN116158532A (en) | 2023-03-21 | 2023-03-21 | Application of lactobacillus plantarum grx16 in preparation of food, functional food and medicine with insulin resistance relieving function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116158532A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105053202A (en) * | 2015-09-01 | 2015-11-18 | 扬州大学 | Preparation method of high-quality fermented camel milk with function of auxiliarily lowering blood sugar |
| CN105132318A (en) * | 2015-09-01 | 2015-12-09 | 扬州大学 | Lactobacillus plantarum grx16 and application thereof |
| CN114381395A (en) * | 2021-12-30 | 2022-04-22 | 杭州康源食品科技有限公司 | Lactobacillus plantarum ZJUFN1 and application thereof |
-
2023
- 2023-03-21 CN CN202310279050.7A patent/CN116158532A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105053202A (en) * | 2015-09-01 | 2015-11-18 | 扬州大学 | Preparation method of high-quality fermented camel milk with function of auxiliarily lowering blood sugar |
| CN105132318A (en) * | 2015-09-01 | 2015-12-09 | 扬州大学 | Lactobacillus plantarum grx16 and application thereof |
| CN114381395A (en) * | 2021-12-30 | 2022-04-22 | 杭州康源食品科技有限公司 | Lactobacillus plantarum ZJUFN1 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114317353B (en) | Lactobacillus plantarum ZJFFYJ 7 and application thereof | |
| CN103314099B (en) | Lactic bacterium having an effect of ameliorating metabolic syndrome | |
| Li et al. | Effect of soybean milk fermented with Lactobacillus plantarum HFY01 isolated from yak yogurt on weight loss and lipid reduction in mice with obesity induced by a high-fat diet | |
| CN109593678B (en) | Bifidobacterium longum YH295 and application thereof in preparing product for reducing abdominal obesity risk | |
| CN109125525B (en) | Composition for preventing and treating cardiovascular diseases and preparation method and application thereof | |
| CN104721652A (en) | Lactobacillus fermented barley meal as well as preparation method and application thereof | |
| CN115428949B (en) | Probiotic traditional Chinese medicine composition with weight-losing function and preparation method thereof | |
| CN104621566A (en) | Lactobacillus-fermented barley extract as well as preparation method and application thereof | |
| CN108283285A (en) | A kind of health-care physiotherapeutic food of diabetes | |
| CN115011532B (en) | Lactobacillus paracasei JY062 preparation, and preparation method and application thereof | |
| TW201705969A (en) | Novel Lactobacillus mali APS1 and use thereof | |
| CN114381395B (en) | Lactobacillus plantarum ZJFFN 1 and application thereof | |
| CN116077536A (en) | Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof | |
| CN116195743A (en) | Application of lactobacillus fermentum grx08 in preparation of functional foods and medicines for relieving obesity and glycolipid metabolic disorders | |
| CN110810629A (en) | Probiotic preparation and application thereof | |
| CN108713755A (en) | Quinoa weight reducing nutrition milk shake | |
| CN116211956B (en) | Composition for regulating intestinal tract and/or improving obesity, preparation method, chewable tablet and application thereof | |
| CN112514995A (en) | Suckling pig immune milk powder rich in probiotics and prebiotics and preparation method thereof | |
| KR20100054428A (en) | Extracts for improving glucose homeostasis fermented using lactobacillus gasseri kctc 3163 from ginseng or ginseng extract | |
| CN116286458B (en) | Lactobacillus plantarum LZ010 capable of reducing blood pressure and blood fat and application thereof | |
| CN115337327B (en) | Preparation method and application of probiotic preparation with lipid-lowering, anti-inflammatory and antioxidant functions | |
| CN109965290B (en) | Meal replacement powder for improving intestinal flora and application thereof | |
| CN116158532A (en) | Application of lactobacillus plantarum grx16 in preparation of food, functional food and medicine with insulin resistance relieving function | |
| CN116508993A (en) | Application of lactobacillus reuteri in preparation of probiotics with metabolism regulating effect | |
| CN106173853B (en) | Nutritional composition for reducing blood fat and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |